TY - JOUR
T1 - Collaborative university–industry R&D practices supporting the pharmaceutical innovation process
T2 - Insights from a bibliometric review
AU - Ma, Zhongxuan
AU - Augustijn, Kevin
AU - de Esch, Iwan J.P.
AU - Bossink, Bart
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/8
Y1 - 2022/8
N2 - University–industry collaborative research and development (UIC R&D) is generally seen as a driver of the pharmaceutical innovation process. Here, we perform a bibliometric review of UIC R&D practices over the past 30 years (1991–2020) by analyzing 800+ publications. At the strategic level of organizational cooperation patterns, the analysis shows that pharmaceutical UIC R&D mainly aims at strategic alliance formation, which gears toward universities and companies collaboratively exploring and commercializing technological breakthroughs. At the structural level of universities and companies investing in cooperation and aligning their activities, analytical results indicate that universities and companies organize themselves as interdependent entities in an open innovation ecosystem. At the cultural level of generally accepted collaboration norms and habits, analytical results show that university–company partnerships are becoming a rule rather than an exception. This study delves into a 30-year history of UIC R&D practices that support the pharmaceutical innovation process. It provides academics and practitioners with an insight into possible strategies for UIC R&D in the future and presents avenues for science, business and innovation research.
AB - University–industry collaborative research and development (UIC R&D) is generally seen as a driver of the pharmaceutical innovation process. Here, we perform a bibliometric review of UIC R&D practices over the past 30 years (1991–2020) by analyzing 800+ publications. At the strategic level of organizational cooperation patterns, the analysis shows that pharmaceutical UIC R&D mainly aims at strategic alliance formation, which gears toward universities and companies collaboratively exploring and commercializing technological breakthroughs. At the structural level of universities and companies investing in cooperation and aligning their activities, analytical results indicate that universities and companies organize themselves as interdependent entities in an open innovation ecosystem. At the cultural level of generally accepted collaboration norms and habits, analytical results show that university–company partnerships are becoming a rule rather than an exception. This study delves into a 30-year history of UIC R&D practices that support the pharmaceutical innovation process. It provides academics and practitioners with an insight into possible strategies for UIC R&D in the future and presents avenues for science, business and innovation research.
KW - Big pharma
KW - Drug development
KW - Innovation ecosystem
KW - Strategic management
KW - University–industry collaboration
UR - http://www.scopus.com/inward/record.url?scp=85130417413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130417413&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2022.05.001
DO - 10.1016/j.drudis.2022.05.001
M3 - Review article
C2 - 35550437
AN - SCOPUS:85130417413
SN - 1359-6446
VL - 27
SP - 2333
EP - 2341
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 8
ER -